[
    "{\"step_by_step_thinking\": \"Document 0 states that avelumab, a PD-L1 inhibitor, has been shown to prolong overall survival in patients with advanced urothelial carcinoma. Document 1 also mentions that avelumab has shown promising antitumor activity in patients with urothelial carcinoma. Document 2 further supports this by stating that avelumab has shown clinical efficacy for metastatic and advanced urothelial carcinoma. Document 3 mentions that avelumab has become the standard of care for advanced or metastatic urothelial carcinoma. Document 4 states that avelumab was approved by the FDA for the treatment of locally advanced or metastatic urothelial carcinoma. Document 5 mentions that avelumab has led to improvements in overall survival in patients with metastatic urothelial cancer. Document 6 also supports the effectiveness of avelumab in the treatment of patients with platinum-refractory metastatic urothelial carcinoma. Document 7 mentions that avelumab has shown antitumor activity in the treatment of patients with locally advanced or metastatic urothelial carcinoma. Document 8 states that avelumab is an attractive option for patients with metastatic urothelial carcinoma. Document 9 mentions that avelumab has shown promising results in the treatment of urothelial cancer. Document 10 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 11 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 12 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 13 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 14 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 15 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 16 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 17 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 18 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 19 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 20 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 21 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 22 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 23 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 24 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 25 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 26 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 27 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 28 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 29 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma. Document 30 states that avelumab has shown promising results in the treatment of advanced urothelial carcinoma. Document 31 mentions that avelumab has shown promising results in the treatment of metastatic urothelial carcinoma.\", \"answer_choice\": \"A\"}"
]